Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced the commercial availability of DecisionDx® DiffDx™-Melanoma, a diagnostic test designed to assist dermatopathologists in evaluating suspicious pigmented lesions. This gene expression profile test can classify lesions as benign, intermediate-risk, or malignant, with a reported accuracy of 96.6%. The test aims to enhance diagnostic clarity, potentially impacting patient treatment decisions significantly. With approximately 300,000 challenging cases yearly in the U.S., this innovation could improve patient outcomes and reduce melanoma-specific mortality risks.
Castle Biosciences (Nasdaq: CSTL) announced its participation in the ASDP 57th Virtual Annual Meeting, showcasing two significant poster presentations. The presentations include DecisionDx®-Melanoma, focusing on predictors of sentinel lymph node metastasis, and DecisionDx® DiffDx™-Melanoma, which discusses a diagnostic gene expression profile for challenging pigmented lesions. Both presentations are set for November 9 and 10, 2020, highlighting the company's commitment to advancing skin cancer diagnostics through genomic testing.
Castle Biosciences (Nasdaq: CSTL) is set to release its third-quarter financial results on November 9, 2020. The results will be available after market close, followed by a conference call and webcast at 4:30 PM ET. The company specializes in skin cancer diagnostics, providing genomic information to enhance treatment decisions. Additionally, Castle offers tests for various melanomas and is developing solutions for other cancers.
Castle Biosciences, Inc. (Nasdaq: CSTL) has announced an investor webcast scheduled for Oct. 28, 2020, at 4:30 p.m. ET to discuss the launch of its ConfirmDx®-Melanoma test, set to be available in Q4 2020. This test aims to help dermatopathologists classify difficult-to-diagnose pigmented lesions, as approximately 300,000 of 2 million biopsied annually in the U.S. present diagnostic challenges. The webcast will feature guest speaker Dr. Sarah I. Estrada, along with a Q&A session.
Castle Biosciences (Nasdaq: CSTL) presented data on DecisionDx®-Melanoma at the 16th EADO Congress, demonstrating its ability to identify patients with T1-T2 melanoma at low risk of sentinel lymph node (SLN) positivity. In a study involving 2,303 patients, only 1.8% of low-risk patients over 65 had positive SLN results, compared to 14.6% in high-risk individuals. This test, validated in over 5,700 samples, aids in sparing patients unnecessary SLNB surgeries, potentially lowering healthcare costs. Recent Medicare coverage expansion for this test underscores its significance.
Castle Biosciences, Inc. (CSTL) highlighted its innovative tests during the 2020 ASDS Virtual Annual Meeting, showcasing findings on DecisionDx-Melanoma and DecisionDx-SCC. The DecisionDx-Melanoma test indicated that 69% of melanoma patients could avoid sentinel lymph node biopsies with a Class 1A result, boasting a 98% five-year survival predictive value. Additionally, DecisionDx-SCC demonstrated strong prognostic capabilities, stratifying patients into risk classes with significant survival differences: 93.9% for low risk, compared to 47.8% for high risk. These tests aim to enhance personalized cancer treatment approaches.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that Palmetto GBA MolDx issued a final expanded local coverage determination for its DecisionDx®-Melanoma test, effective Nov. 22, 2020. This gene expression profile test predicts the risk of metastasis and recurrence in melanoma patients, having been studied in over 5,700 samples. CEO Derek Maetzold expressed satisfaction over the expanded coverage, which enhances access for Medicare beneficiaries. The company continues to support the test's clinical utility with 26 peer-reviewed publications.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its participation in the 2020 ASDS Virtual Annual Meeting, where it will present data on its genomic tests for skin cancer. Notable presentations include:
- Clinical validation of a 40-gene test for cSCC by Sherrif Ibrahim, M.D., Ph.D., on October 9, 2020.
- Prognostic model combining a 31-gene test with sentinel lymph node biopsy by Aaron Farberg, M.D., also on October 9, 2020.
The presentations will be available for registrants for 30 days post-meeting.